Mirum Grants Options to 14 New Hires at $100.61

Mirum Pharmaceuticals (Nasdaq: MIRM) granted equity awards to 14 new employees as part of a strategic effort to secure specialized talent for its rare disease portfolio. The Compensation Committee approved the inducement awards on September 10, 2026, in compliance with Nasdaq Listing Rule 5635(c)(4), which permits such grants to facilitate new hires without immediate shareholder approval. This move aligns employee interests with long-term company performance while addressing specific recruitment needs in the company’s clinical and commercial divisions.

The package consists of non-qualified stock options to purchase 28,512 shares and 37,375 restricted stock units (RSUs). Each option carries an exercise price of $100.61, matching the closing price of Mirum’s common stock on the grant date. According to reports from GN stocks/nasdaq, these awards are structured to vest over three to four years, ensuring that the financial benefits are contingent upon the employees’ continued service with the company. This vesting schedule is designed to retain key personnel during critical stages of drug development and commercial expansion.

Option Vesting Terms and Pricing

The stock options vest over a four-year period, with 25% of the underlying shares becoming exercisable on the first anniversary of the vesting commencement date. The remaining balance vests monthly over the subsequent 36 months. This staggered vesting schedule provides a continuous retention incentive, tying the realization of value to sustained employment. The exercise price of $100.61 reflects the market value at the time of the grant, establishing a clear benchmark for the potential upside these employees can capture as the company’s valuation evolves.

Unlike standard employee stock options, these non-qualified awards do not offer specific tax advantages but are taxed as income upon exercise. This structure simplifies the compensation framework while maintaining alignment with broader market practices for biotechnology firms. The pricing mechanism ensures that the awards are intrinsic to the company’s current market position, rather than a speculative valuation, providing a transparent foundation for the financial incentives offered to these new hires.

RSU Structure and Retention Focus

The restricted stock units will vest over three years, with 33% of the shares releasing on each anniversary of the initial vesting date. This tri-annual vesting schedule offers a different risk profile compared to the options, as RSUs retain value even if the stock price falls below the grant price, provided the employee remains with the company. This component of the compensation package is crucial for stabilizing the workforce, particularly for roles that require long-term commitment to clinical trials and regulatory processes.

The combination of options and RSUs creates a balanced incentive structure. Options provide leveraged upside potential, rewarding employees for significant growth in share price, while RSUs provide a baseline of equity value that accumulates over time. This dual approach is typical for companies in the pharmaceutical sector that are transitioning between clinical development and commercial maturity, such as Mirum, which is advancing multiple late-stage assets.

Strategic Context for Rare Disease Hires

Mirum’s pipeline includes several advanced candidates, such as volixibat for primary sclerosing cholangitis and brelovitug for chronic hepatitis delta virus. Attracting and retaining top-tier talent is essential for navigating the complex regulatory and clinical landscapes associated with these therapies. The inducement awards signal a commitment to building a robust team capable of executing on these high-impact projects. By offering competitive equity packages, the company aims to position itself as an employer of choice in the competitive rare disease space.

The company’s commercial portfolio, which includes LIVMARLI, CHOLBAM, and CTEXLI, also requires ongoing operational expertise to manage sales, marketing, and medical affairs. The new hires are likely to play key roles in these areas, contributing to the revenue generation that supports the company’s broader R&D efforts. This strategic hiring initiative underscores Mirum’s focus on integrating commercial success with scientific innovation to drive long-term shareholder value.